Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

Marcello Tiseo, Francesco Gelsomino, Marco Bartolotti, Paola Bordi, Melissa Bersanelli, Giulio Rossi, Andrea Ardizzoni

Research output: Contribution to journalArticle

Abstract

The anaplastic lymphoma kinase (ALK) gene rearrangement identifies a distinct molecular subset in non-small-cell lung cancer (NSCLC) populations susceptible to targeted inhibition. It consists of a small inversion in the short arm of chromosome 2 between exon 20 of the ALK gene and different exons of the echinoderm microtubule-associated protein-like (EML4) gene. This translocation leads to a chimeric protein with constitutive activation of ALK that possesses an oncogenic activity demonstrated both in vitro and in vivo. Other rare translocation partners for ALK other than EML4 may be found in lung cancers, including TRK-fused gene (TFG) and kinesin family member 5B (KIF5B). ALK-positive patients represent 5-6% of all NSCLCs and they seem to have particular clinicopathological and molecular features. Recently, Phase I-II trial results of crizotinib, a potent dual c-MET and ALK inhibitor, demonstrated its dramatic efficacy in ALK-positive patients with advanced NSCLC. This article will present knowledge on the characteristics of ALK-positive patients, discuss the different methods of ALK rearrangement detection and focus on clinical results of crizotinib.

Original languageEnglish
Pages (from-to)1677-1687
Number of pages11
JournalExpert Review of Anticancer Therapy
Volume11
Issue number11
Publication statusPublished - Nov 2011

Fingerprint

Non-Small Cell Lung Carcinoma
Therapeutics
Exons
Genes
anaplastic lymphoma kinase
Kinesin
Microtubule-Associated Proteins
Chromosomes, Human, Pair 2
Gene Rearrangement
Lung Neoplasms
Population

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology

Cite this

Tiseo, M., Gelsomino, F., Bartolotti, M., Bordi, P., Bersanelli, M., Rossi, G., & Ardizzoni, A. (2011). Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. Expert Review of Anticancer Therapy, 11(11), 1677-1687.

Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. / Tiseo, Marcello; Gelsomino, Francesco; Bartolotti, Marco; Bordi, Paola; Bersanelli, Melissa; Rossi, Giulio; Ardizzoni, Andrea.

In: Expert Review of Anticancer Therapy, Vol. 11, No. 11, 11.2011, p. 1677-1687.

Research output: Contribution to journalArticle

Tiseo, M, Gelsomino, F, Bartolotti, M, Bordi, P, Bersanelli, M, Rossi, G & Ardizzoni, A 2011, 'Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.', Expert Review of Anticancer Therapy, vol. 11, no. 11, pp. 1677-1687.
Tiseo M, Gelsomino F, Bartolotti M, Bordi P, Bersanelli M, Rossi G et al. Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. Expert Review of Anticancer Therapy. 2011 Nov;11(11):1677-1687.
Tiseo, Marcello ; Gelsomino, Francesco ; Bartolotti, Marco ; Bordi, Paola ; Bersanelli, Melissa ; Rossi, Giulio ; Ardizzoni, Andrea. / Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer. In: Expert Review of Anticancer Therapy. 2011 ; Vol. 11, No. 11. pp. 1677-1687.
@article{4e5731ed75694fff818a01708b47c1ed,
title = "Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.",
abstract = "The anaplastic lymphoma kinase (ALK) gene rearrangement identifies a distinct molecular subset in non-small-cell lung cancer (NSCLC) populations susceptible to targeted inhibition. It consists of a small inversion in the short arm of chromosome 2 between exon 20 of the ALK gene and different exons of the echinoderm microtubule-associated protein-like (EML4) gene. This translocation leads to a chimeric protein with constitutive activation of ALK that possesses an oncogenic activity demonstrated both in vitro and in vivo. Other rare translocation partners for ALK other than EML4 may be found in lung cancers, including TRK-fused gene (TFG) and kinesin family member 5B (KIF5B). ALK-positive patients represent 5-6{\%} of all NSCLCs and they seem to have particular clinicopathological and molecular features. Recently, Phase I-II trial results of crizotinib, a potent dual c-MET and ALK inhibitor, demonstrated its dramatic efficacy in ALK-positive patients with advanced NSCLC. This article will present knowledge on the characteristics of ALK-positive patients, discuss the different methods of ALK rearrangement detection and focus on clinical results of crizotinib.",
author = "Marcello Tiseo and Francesco Gelsomino and Marco Bartolotti and Paola Bordi and Melissa Bersanelli and Giulio Rossi and Andrea Ardizzoni",
year = "2011",
month = "11",
language = "English",
volume = "11",
pages = "1677--1687",
journal = "Expert Review of Molecular Diagnostics",
issn = "1473-7159",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.

AU - Tiseo, Marcello

AU - Gelsomino, Francesco

AU - Bartolotti, Marco

AU - Bordi, Paola

AU - Bersanelli, Melissa

AU - Rossi, Giulio

AU - Ardizzoni, Andrea

PY - 2011/11

Y1 - 2011/11

N2 - The anaplastic lymphoma kinase (ALK) gene rearrangement identifies a distinct molecular subset in non-small-cell lung cancer (NSCLC) populations susceptible to targeted inhibition. It consists of a small inversion in the short arm of chromosome 2 between exon 20 of the ALK gene and different exons of the echinoderm microtubule-associated protein-like (EML4) gene. This translocation leads to a chimeric protein with constitutive activation of ALK that possesses an oncogenic activity demonstrated both in vitro and in vivo. Other rare translocation partners for ALK other than EML4 may be found in lung cancers, including TRK-fused gene (TFG) and kinesin family member 5B (KIF5B). ALK-positive patients represent 5-6% of all NSCLCs and they seem to have particular clinicopathological and molecular features. Recently, Phase I-II trial results of crizotinib, a potent dual c-MET and ALK inhibitor, demonstrated its dramatic efficacy in ALK-positive patients with advanced NSCLC. This article will present knowledge on the characteristics of ALK-positive patients, discuss the different methods of ALK rearrangement detection and focus on clinical results of crizotinib.

AB - The anaplastic lymphoma kinase (ALK) gene rearrangement identifies a distinct molecular subset in non-small-cell lung cancer (NSCLC) populations susceptible to targeted inhibition. It consists of a small inversion in the short arm of chromosome 2 between exon 20 of the ALK gene and different exons of the echinoderm microtubule-associated protein-like (EML4) gene. This translocation leads to a chimeric protein with constitutive activation of ALK that possesses an oncogenic activity demonstrated both in vitro and in vivo. Other rare translocation partners for ALK other than EML4 may be found in lung cancers, including TRK-fused gene (TFG) and kinesin family member 5B (KIF5B). ALK-positive patients represent 5-6% of all NSCLCs and they seem to have particular clinicopathological and molecular features. Recently, Phase I-II trial results of crizotinib, a potent dual c-MET and ALK inhibitor, demonstrated its dramatic efficacy in ALK-positive patients with advanced NSCLC. This article will present knowledge on the characteristics of ALK-positive patients, discuss the different methods of ALK rearrangement detection and focus on clinical results of crizotinib.

UR - http://www.scopus.com/inward/record.url?scp=84856893071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856893071&partnerID=8YFLogxK

M3 - Article

C2 - 22050016

AN - SCOPUS:84856893071

VL - 11

SP - 1677

EP - 1687

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

SN - 1473-7159

IS - 11

ER -